Omnicell, Inc. (OMCL) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

65OpportunityDD: Jun 08, 2026Analyst: 75

paidPrice at analysis date

USD 41.5 (08/06/2026)

domainMkt cap

$1.94B

pie_chartShares

45.44M

candlestick_chart52W

$22.66-$55.00

trending_downShort interest

6.5%

INFONASDAQHealth Care3580 employeesFounded 1992

Verdict: MODERATE — Quality compounder, fairly priced

Profitable healthcare-tech leader in medication management showing accelerating momentum: Q1 CY2026 beat by 89% on non-GAAP EPS ($0.55 vs $0.29 est), revenue +15% YoY to $310M, gross margin expanded 416 bps, FY26 guidance raised to $1.215–1.255B / EBITDA $153–168M / EPS $1.80–2.00. Balance sheet net cash ($67M), Titan XT cycle is rewriting the platform narrative. However, with stock at $41.53 (post-rally pullback from $45.51 high), forward EV/EBITDA ~11.7x sits near peer median — most of the re-rating has already happened. Fair value ≈ $44, gap +6%, base case is "hold the compounder, don't chase".

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-06-08

Omnicell, Inc. (OMCL)

Healthcare Technology · NASDAQ · Fort Worth, TX

"Solid quality compounder with momentum; valuation already reflects the upgrade cycle."

Q1 beat +89% Net cash $67M Guidance raised PE fw ~22x Titan XT cycle

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value Estimate — EV/EBITDA (peer-derived multiple on FY26E guidance midpoint)

Fair value base case

USD 44.0

Range: USD 33.0-USD 54.0

Price at analysis date: USD 41.5 (08/06/2026)

Base upside/downside: +6%

Methodology: EV/EBITDA on FY26E guidance midpoint ($160M EBITDA × 12.0x multiple = $1.92B EV), plus net cash ($67M), plus option value on AI/Titan ramp (prob-weighted), minus dilution haircut on 1% conv. notes due 2029. Multiple derived from healthcare-tech peer median (BDX 14x, MCK 13x, CAH 10x — median ~12x ex VEEV outlier). Cross-check: forward P/E $44/$1.90 = 23.2x, comparable to peer fw P/E range 20–25x. Sensitivity within ±16% for ±2x multiple. ⚠️ Not investment advice.

Component	Assumption	USD/share
Core enterprise value	12.0x EV/EBITDA fw × $160M FY26E adj. EBITDA (guidance midpoint $153–168M)	+$42.25
Net cash position	($239M cash − $172.5M convertibles 1% 2029) / 45.44M shares	+$1.47
Service mix uplift (recurring)	Services/SaaS now ~25% rev (Q1 2026) vs ~18% in 2023; 0.5x multiple uplift inside the 12x vs peer median 11x	included above
Convertible dilution risk	$172.5M conv. @ ~$58 conversion price; ~3M diluted shares if ITM; expected NPV-adj haircut ~25% prob × $0.30/sh	−$0.08
AI/Titan platform option (base)	7% probability × $50M incremental EBITDA × 12x ÷ 45.44M shares (rest of optionality lives in Bull scenario)	+$0.92
FV base case	Sum: 42.25 + 1.47 − 0.08 + 0.92 = $44.56, rounded to $44	≈ $44.00

Bull

$52–58

Probability: 20%

EBITDA hits high end of guidance ($168M+), Titan XT upgrade cycle drives multi-quarter beat-and-raise, service mix accelerates to 30%+, multiple expands to 14x. Stock retraces toward 52w high.

Base

USD 37.4-USD 50.6

Probability: 50%

Guidance midpoint executed ($160M EBITDA), multiple holds at peer median (~12x). Hospital capex absorbs tariff pressure but not enough to surprise upside. Total return ≈ +5–15% over 12 months.

Bear

$30–35

Probability: 30%

Hospital budget freeze, tariff drag on hardware GM, services growth stalls. EBITDA falls to $145M, multiple compresses to 10x. Re-rating reverses; stock drifts back to $30s. The momentum thesis breaks.

Methodology: Methodology: EV/EBITDA on FY26E guidance midpoint ($160M EBITDA × 12.0x multiple = $1.92B EV), plus net cash ($67M), plus option value on AI/Titan ramp (prob-weighted), minus dilution haircut on 1% conv. notes due 2029. Multiple derived from healthcare-tech peer median (BDX 14x, MCK 13x, CAH 10x — median ~12x ex VEEV outlier). Cross-check: forward P/E $44/$1.90 = 23.2x, comparable to peer fw P/E range 20–25x. Sensitivity within ±16% for ±2x multiple. ⚠️ Not investment advice. Not investment advice.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

~6.5%

~2.9M shares short on 45.44M out (Fintel/Nasdaq estimate May 2026). Days-to-cover ~4. Moderate level — no squeeze setup, but reflects healthy skepticism post Q4 2025 miss.

🟢 Share dilution (1Y)

+1.1%

From ~44.95M to 45.44M shares YoY. Primarily equity comp; no shelf offering. Conv. notes 1% 2029 ($172.5M) could add ~3M diluted shares if ITM (conv. price ~$58).

🟢 Buyback

$75M auth.

New repurchase program announced May 2025. Not aggressively used in 2025 due to debt repayment priority ($175M conv. 2025 paid at maturity). Capacity remains for FY26 if multiple compresses.

Short Interest — context

OMCL — 6.5%

6.5%

Moderate short interest (5–15% band). No squeeze potential. Suggests market is split between Q1 2026 beat narrative and Q4 2025 miss memory. No 13D activist filings, no material insider selling reported in 12M period (last Form 4 sales were routine 10b5-1 plans for <$300K each).

$Financial analysis — FY 2025 + Q1 2026

Revenue FY25

$1.185B

+6.6% YoY

Adj. EBITDA FY25

$140M

+2.9% YoY (margin 11.8%)

Net cash

$67M

$239M cash − $172.5M conv.

Q1 2026 EPS beat

+89%

$0.55 vs $0.29 est

Item	FY2023	FY2024	FY2025	Q1 2026 (act.)	Guidance FY2026
Revenue ($M)	1,150	1,112	1,185	310	1,215 – 1,255
Adj. EBITDA ($M)	~125	136	140	44.7	153 – 168
Non-GAAP EPS ($)	~1.55	1.71	1.62	0.55	1.80 – 2.00
GAAP Net Income ($M)	~−9	12.5	2.05	11.4	N/D
Gross margin %	~42%	43.5%	43.2%	45.3%	~44–45%
Cash & equiv ($M)	~380	~370	~370	239	—
Total debt ($M)	347.5	347.5	172.5	172.5	—

Note: $175M of 0.25% Convertible Senior Notes 2025 were repaid at maturity in 2025; balance now is $172.5M 1.00% Convertible Senior Notes 2029. FY2023 figures partially estimated.

Quarterly dynamics — last 5 quarters
Metric	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue ($M)	270	295	306	314	310
Gross margin %	41.1%	43.0%	43.5%	43.4%	45.3%
Non-GAAP EPS ($)	0.26	0.40	0.56	0.40	0.55
End-of-period cash ($M)	372	389	403	225	239

Financial position and sustainability

FY26E EBITDA / FY25 EBITDA

+14.3%

Q1 26 EBITDA / Q1 25

~+95%

Q1 26 GM expansion vs Q1 25

+416 bps

Net cash / Market cap

3.5%

account_tree

Business model — Pharmacy automation & medication management platform

Vertical leader in hospital medication management automation

Omnicell is the #1 pure-play vendor of automated dispensing systems (ADS) and central pharmacy automation for US hospitals. Core franchise: XT/XTExtend/Titan XT automated dispensing cabinets installed at 7,000+ healthcare facilities globally. Pivoting from one-time hardware sales to recurring "Autonomous Medication Management" subscription model: Central Pharmacy Dispensing Service, IV Compounding Service, specialty pharmacy services. Titan XT (launched Dec 2025) is the platform refresh that triggers a multi-year replacement cycle on installed base + new logo wins. Key competitor: BDX Pyxis. Switching costs are very high (workflow integration, EHR connectivity, controlled-substance compliance).

Connected Devices (hardware) ~$610–625M FY26E (~50% rev) 🟢 ramping XT/Titan XT cabinets, ancillary devices. GM ~35–40%. Titan XT cycle drives FY26 reacceleration; tariff exposure on components is a watch item. Technical Services ~$310–325M FY26E (~25% rev) 🟢 ramping Maintenance, upgrades, post-install support. Recurring, high attach. GM ~50%. Highest margin contributor and most predictable revenue. SaaS & Expert Services ~$185–200M FY26E (~15% rev) 🟢 ramping OmniSphere cloud, EnlivenHealth, specialty pharmacy services, IV Compounding Service. Strategic growth segment. GM 55%+. Strategic re-rating lever. Consumables ~$110–125M FY26E (~10% rev) 🟡 stable Single-use medication packaging, pouches. Razor-blade economics tied to installed base. GM ~45%. Modest growth, locked-in customers. International (cross-cut) ~$110–130M FY26E (~9% rev) 🟡 small but growing EMEA + select APAC. Penetration far below US share. Subject to currency and slower hospital cycles. Optional upside, not in base case. AI / Autonomous platform option value 🟡 ramping Autonomous Medication Management framework + AI-driven inventory/error-reduction. Real revenue impact 2027+. Captured as option in FV.

gavel

Legal, regulatory and risk analysis

Hospital capex slowdown

High

Provider capital budgets remain pressured by labor inflation and Medicare reimbursement squeeze. A 12–18 month deferral cycle on ADS upgrades would knock 5–8% off FY26 hardware revenue and meaningfully reset multiple.

Tariff drag on hardware GM

Moderate

Mentioned in Q1 2026 prepared remarks: tariff headwinds partially masking platform transition. Components sourced internationally; an escalation could compress GM 100–150 bps in H2 2026.

Competitive pressure from BDX Pyxis

Moderate

BDX is well-funded incumbent with broader hospital relationships. Aggressive pricing on competitive replacement deals could trim OMCL share gains. Titan XT must demonstrate clear functional gap.

Customer concentration / GPO power

Moderate

IDNs and GPOs (Vizient, Premier, HealthTrust) negotiate hard on multi-year deals. Larger account sizes are good for visibility but bad for unit pricing during contract renewals.

Convertible notes dilution

Low

$172.5M 1% convertibles due 2029, conversion price ~$58. Stock at $41.53 is well below strike; dilution risk is real only if stock rises >40%. Manageable and modeled in FV.

Service-mix execution risk

Moderate

The thesis depends on services growing to 30%+ of revenue with stable 50%+ GM. Implementation/ramp delays on Central Pharmacy Dispensing Service or IV Compounding can defer the re-rating by 12–24 months.

Balance sheet strength

Positive

Net cash $67M after repaying $175M conv. 2025 at maturity. Only $172.5M long-term debt at 1% coupon due 2029. No covenant risk, no refinancing wall. Capital available for buybacks or tuck-in M&A.

Quality of beat — clean Q1 2026

Positive

Q1 2026 beat was driven by revenue +15%, GM expansion 416 bps, OCF doubling, not by one-off items. Earnings quality is high. Raised guidance is the strongest signal.

article

SWOT analysis

Strengths

+#1 US share in automated dispensing systems with very high switching costs
+Net cash balance sheet ($67M), $172.5M long-term debt at 1% coupon — no leverage stress
+Q1 2026 EPS beat 89%; OCF doubled; GM expansion 416 bps — high-quality beat
+Titan XT launch triggers multi-year platform refresh cycle on installed base of 7,000+ sites
+Recurring services mix expanding (Technical + SaaS ≈ 40% of revenue, 50%+ GM)

Weaknesses

−GAAP TTM net income still depressed ($2M); EPS power not fully visible yet
−FY25 non-GAAP EPS down YoY ($1.62 vs $1.71) — multi-year EPS only just inflecting
−Hardware GM (~35–40%) lower than software/services peers
−CFO transition completed late 2025; new finance team still building credibility
−Forward P/E ~22x prices in execution: little margin of safety from valuation alone

Opportunities

→Beat-and-raise pattern in FY26 quarterly cadence could lift consensus EBITDA toward $170M+
→Autonomous Medication Management / AI platform real revenue contribution 2027+
→International penetration is structurally low — multi-year addressable market
→Specialty pharmacy services attach rate has further to go inside the installed base
→$75M buyback authorization not deployed — accretive if multiple compresses

Threats

!Hospital capex freeze: ADS upgrades are deferrable, recession-sensitive
!Tariff escalation pressures hardware GM — explicitly cited in management commentary
!BDX Pyxis pricing aggression on competitive replacements
!Multiple compression risk: if growth disappoints, 11.7x EV/EBITDA quickly becomes 9x
!Convertible dilution if stock breaks above $58 (positive for shareholders but caps upside)

article

Summary by assessment area

🟢 Financial risk — LOW

Net cash $67M, debt $172.5M at 1% coupon to 2029
No covenant or refinancing wall
OCF doubled in Q1 2026; FY26 guidance raised
$75M buyback authorization untapped

🟡 Execution risk — MODERATE

Titan XT cycle must convert into actual revenue acceleration H2 2026
Services mix must hit ~30% rev to justify multiple expansion
Tariff drag on hardware GM in H2 still uncertain
New CFO building credibility with the Street

🟡 Valuation risk — MODERATE

FV $44 vs price $41.53 — gap only +6%, fairly priced
11.7x EV/EBITDA fw, in-line with peer median
Sell-side mean target $51 (+23%) — more optimistic, but multiple-driven
No clear margin of safety vs base case; bull case needs beat-and-raise continuity

2026-07-30 earnings

Q2 2026 Earnings Release

short-term Impact: High Direction: Binary

First confirmation of the beat-and-raise pattern. Watch: services mix %, GM expansion sustainability, Titan XT bookings, FY26 guidance refresh. Another beat triggers $48+ retest; in-line/miss sends stock back to $35–38.

2026-09-15 product

Titan XT large-IDN adoption milestone

medium-term Impact: High Direction: Bullish

Management likely to announce flagship IDN deployments at H2 healthcare-IT conferences. Validates the platform refresh thesis and supports 2027 revenue acceleration narrative.

2026-12-08 strategic

ASHP Midyear 2026 — AI / Autonomous Medication Management updates

medium-term Impact: Medium Direction: Bullish

Industry's flagship pharmacy event. OMCL traditionally launches AI/automation roadmap updates here. Real product news could support 2027 services-revenue revision.

2026-10-29 guidance

FY26 Guidance Refresh at Q3 2026 print

medium-term Impact: High Direction: Binary

If Q1+Q2 trend continues, FY26 EBITDA guidance midpoint likely lifted toward $165M+. Direct multiple-expansion catalyst. Conversely, a tariff-driven cut would compress the stock 15–20%.

2026-08-31 capital_markets

Buyback activation under $75M authorization

short-term Impact: Medium Direction: Bullish

$75M authorization untouched. Any pullback toward $35–38 could trigger meaningful execution, supporting stock floor and signaling management conviction.

2026-11-30 ma

Sector M&A — possible strategic interest

long-term Impact: Medium Direction: Bullish

Pure-play healthcare-IT platforms have attracted PE and strategic interest in 2024–2026. OMCL at $1.9B mkt cap is digestible; sponsorship optionality exists but is not the base thesis.

2026-08-15 macro

Tariff/component-cost escalation

short-term Impact: Medium Direction: Bearish

A further round of tariffs on imported electronic components could compress hardware GM 100–150 bps and force a guidance trim. Watch headline risk through Q3.

{ "verdict_label": {"it": "Giudizio: MODERATO — Quality compounder, fairly priced", "en": "Verdict: MODERATE — Quality compounder, fairly priced"}, "verdict_text": {"it": "Leader healthcare-tech con beat Q1 2026 +89%, EBITDA in accelerazione, balance sheet net cash. Ma a $41.53 il prezzo riflette già il re-rating: FV ~$44, gap +6%. Hold della qualità, non rincorrere.", "en": "Healthcare-tech leader with Q1 2026 +89% beat, EBITDA accelerating, net-cash balance sheet. But at $41.53 the price already reflects the re-rating: FV ~$44, gap +6%. Hold the quality, don't chase."}, "bull_points": [ {"it": "Q1 2026 EPS beat 89% (+111% YoY), GM +416 bps, OCF raddoppiato, guidance FY26 alzata.", "en": "Q1 2026 EPS beat 89% (+111% YoY), GM +416 bps, OCF doubled, FY26 guidance raised."}, {"it": "Net cash $67M, debito 1% al 2029, $75M buyback non utilizzato.", "en": "Net cash $67M, 1% debt to 2029, $75M buyback untapped."}, {"it": "Titan XT cycle + mix servizi ricorrenti ~40%: re-rating ulteriore se l'execution continua.", "en": "Titan XT cycle + recurring services ~40% mix: further re-rating if execution holds."} ], "bear_points": [ {"it": "Multiplo 11.7x EV/EBITDA fw già a mediana peer: poco margine di sicurezza.", "en": "11.7x EV/EBITDA fw already at peer median: little margin of safety."}, {"it": "Q4 2025 fu un miss EPS (-15% in pre-market): la volatilità sui risultati è alta.", "en": "Q4 2025 was an EPS miss (-15% pre-market): earnings volatility is high."}, {"it": "Capex ospedaliero e tariffe sono headwind concreti su hardware GM.", "en": "Hospital capex and tariffs are real headwinds on hardware GM."} ], "risks": [ {"it": "Hospital capex freeze: ADS sono upgrade deferribili.", "en": "Hospital capex freeze: ADS are deferrable upgrades."}, {"it": "Tariffe sui componenti: GM hardware potrebbe perdere 100–150 bps.", "en": "Component tariffs: hardware GM could lose 100–150 bps."}, {"it": "Multiple compression: 11.7x può diventare 9x se la crescita delude.", "en": "Multiple compression: 11.7x can become 9x if growth disappoints."} ] }

Sources & Disclaimer

Sources: Omnicell 10-Q FY2026 Q1 (sec.gov, filed May 2026), Omnicell Q4 2025 / FY2025 8-K (Feb 2026), Yahoo Finance OMCL quote (live), StockAnalysis.com OMCL statistics, StockStory OMCL Q1 CY2026 earnings note, Simply Wall St valuation page, Investing.com earnings call transcript, BusinessWire Q1 2026 press release. Market data — last verified close 2026-06-05: OMCL $41.53, market cap ~$1.94B, 52W: $22.66–$55.00, 45.44M shares outstanding. Short interest ~6.5% (Fintel/Nasdaq est May 2026). ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.